230 related articles for article (PubMed ID: 19090006)
21. Noradrenaline enhances the expression of the neuronal monocarboxylate transporter MCT2 by translational activation via stimulation of PI3K/Akt and the mTOR/S6K pathway.
Chenal J; Pellerin L
J Neurochem; 2007 Jul; 102(2):389-97. PubMed ID: 17394554
[TBL] [Abstract][Full Text] [Related]
22. KAI1/CD82 decreases Rac1 expression and cell proliferation through PI3K/Akt/mTOR pathway in H1299 lung carcinoma cells.
Choi UJ; Jee BK; Lim Y; Lee KH
Cell Biochem Funct; 2009 Jan; 27(1):40-7. PubMed ID: 19107873
[TBL] [Abstract][Full Text] [Related]
23. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
Bibollet-Bahena O; Almazan G
J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
[TBL] [Abstract][Full Text] [Related]
24. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma.
Feng W; Brown RE; Trung CD; Li W; Wang L; Khoury T; Alrawi S; Yao J; Xia K; Tan D
Ann Clin Lab Sci; 2008; 38(3):195-209. PubMed ID: 18715846
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.
Wislez M; Spencer ML; Izzo JG; Juroske DM; Balhara K; Cody DD; Price RE; Hittelman WN; Wistuba II; Kurie JM
Cancer Res; 2005 Apr; 65(8):3226-35. PubMed ID: 15833854
[TBL] [Abstract][Full Text] [Related]
26. Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD).
Fischer DC; Jacoby U; Pape L; Ward CJ; Kuwertz-Broeking E; Renken C; Nizze H; Querfeld U; Rudolph B; Mueller-Wiefel DE; Bergmann C; Haffner D
Nephrol Dial Transplant; 2009 Jun; 24(6):1819-27. PubMed ID: 19176689
[TBL] [Abstract][Full Text] [Related]
27. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.
Liu LZ; Zhou XD; Qian G; Shi X; Fang J; Jiang BH
Cancer Res; 2007 Jul; 67(13):6325-32. PubMed ID: 17616691
[TBL] [Abstract][Full Text] [Related]
28. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung.
Righi L; Volante M; Rapa I; Tavaglione V; Inzani F; Pelosi G; Papotti M
Endocr Relat Cancer; 2010 Dec; 17(4):977-87. PubMed ID: 20817788
[TBL] [Abstract][Full Text] [Related]
29. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma.
Di Paolo S; Teutonico A; Ranieri E; Gesualdo L; Schena PF
Am J Kidney Dis; 2007 Mar; 49(3):462-70. PubMed ID: 17336708
[TBL] [Abstract][Full Text] [Related]
30. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
[TBL] [Abstract][Full Text] [Related]
31. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
32. Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications.
Ong KW; Teo M; Lee V; Ong D; Lee A; Tan CS; Vathsala A; Toh HC
Clin Cancer Res; 2009 Sep; 15(17):5350-8. PubMed ID: 19706821
[TBL] [Abstract][Full Text] [Related]
33. Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells.
Akca H; Tani M; Hishida T; Matsumoto S; Yokota J
Lung Cancer; 2006 Oct; 54(1):25-33. PubMed ID: 16872715
[TBL] [Abstract][Full Text] [Related]
34. Targeting mTOR signaling in lung cancer.
Marinov M; Fischer B; Arcaro A
Crit Rev Oncol Hematol; 2007 Aug; 63(2):172-82. PubMed ID: 17540577
[TBL] [Abstract][Full Text] [Related]
35. Phosphatidylinositol-3 kinase/Akt/p70S6K/AP-1 signaling pathway mediated benzo(a)pyrene-induced cell cycle alternation via cell cycle regulatory proteins in human embryo lung fibroblasts.
Gao A; Liu B; Shi X; Jia X; Ye M; Jiao S; You B; Huang C
Toxicol Lett; 2007 Apr; 170(1):30-41. PubMed ID: 17383120
[TBL] [Abstract][Full Text] [Related]
36. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma.
Woodard J; Sassano A; Hay N; Platanias LC
Clin Cancer Res; 2008 Jul; 14(14):4640-9. PubMed ID: 18628479
[TBL] [Abstract][Full Text] [Related]
37. Renal activity of Akt kinase in obese Zucker rats.
Zdychová J; Kazdová L; Pelikanová T; Lindsley JN; Anderson S; Komers R
Exp Biol Med (Maywood); 2008 Oct; 233(10):1231-41. PubMed ID: 18641049
[TBL] [Abstract][Full Text] [Related]
38. Akt activation protects pancreatic beta cells from AMPK-mediated death through stimulation of mTOR.
Cai Y; Wang Q; Ling Z; Pipeleers D; McDermott P; Pende M; Heimberg H; Van de Casteele M
Biochem Pharmacol; 2008 May; 75(10):1981-93. PubMed ID: 18377870
[TBL] [Abstract][Full Text] [Related]
39. Modulation of the activities of AMP-activated protein kinase, protein kinase B, and mammalian target of rapamycin by limiting energy availability with 2-deoxyglucose.
Jiang W; Zhu Z; Thompson HJ
Mol Carcinog; 2008 Aug; 47(8):616-28. PubMed ID: 18247380
[TBL] [Abstract][Full Text] [Related]
40. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis.
Rojo F; Najera L; Lirola J; Jiménez J; Guzmán M; Sabadell MD; Baselga J; Ramon y Cajal S
Clin Cancer Res; 2007 Jan; 13(1):81-9. PubMed ID: 17200342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]